Subscribe
shutterstock_1635580639_sundry_photography
Sundry Photography / Shutterstock.com
27 February 2020AmericasSarah Morgan

Genentech in $1.7bn immuno-oncology deal

California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.
Big Pharma
Genentech enters agreement to develop autoimmune therapies
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Asia-Pacific
Roche and Innovent unite in $2bn biospecifics deal
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.
Big Pharma
Genentech enters agreement to develop autoimmune therapies
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Asia-Pacific
Roche and Innovent unite in $2bn biospecifics deal
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.

More on this story

Americas
Bioverativ and Bicycle Therapeutics in $10m haemophilia deal
7 September 2017   Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.
Big Pharma
Genentech enters agreement to develop autoimmune therapies
21 May 2019   US-based biopharmaceutical company Parvus Therapeutics has entered into a collaboration and licensing agreement with Genentech, a subsidiary of Roche.
Asia-Pacific
Roche and Innovent unite in $2bn biospecifics deal
15 June 2020   Swiss healthcare company Roche has partnered with Chinese biotech Innovent Biologics to develop cell therapies and bispecific antibodies.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool